In a report released today, Caroline Palomeque from Maxim Group assigned a Buy rating to Neurotrope (NTRP), with a price target of $16. The company’s shares opened today at $4.20, close to its 52-week low of $3.33.
Palomeque commented:
“Neurotrope announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of Bryostatin-1 in acute lymphoblastic leukemia (ALL).”
According to TipRanks.com, Palomeque has 0 stars on 0-5 star ranking scale with an average return of -14.5% and a 33.3% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Oxford BioMedica plc.
Neurotrope has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Based on Neurotrope’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.17 million. In comparison, last year the company had a GAAP net loss of $4.31 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. It operates through the following geographical segments: US; European Union; Japan; and China and India.
